Microarray patches (MAPs) have promised painless, needle-free drug delivery for nearly three decades. The hard part was never the science — it was making the
June 6–7, 2026 | Kaohsiung Medical University Chung-Ho Memorial Hospital WCC Biomedical marked a significant milestone this June by participating in the Annual Conference of
WCC recently participated in the Taiwan Urologist Association (TUA) gathering at Kuang Tien General Hospital, an event bringing together renowned urologists and industry experts from
WCC Biomedical announced an remarkable achievement as its next-generation pain-relief product WCC-301 successfully completed the US FDA Pre-IND meeting and has now entered GLP toxicology studies,
As Taiwan’s leading researcher and manufacturer of microarray patches (MAPs), we were honored to be invited as a featured speaker at StartUp@Taipei, held in Osaka,
Following the success of Bio-Asia 2025, WCC is moving forward to further showcase our innovations in the healthcare field. We are driving change not only